Subcutaneous (sc) basal and prandial insulin administration is a key component of multiple daily injection (MDI) therapy in patients with type 1 diabetes (T1D) and with insulin-dependent type 2 diabetes (T2D). The gene discussed is INS; the disease is type 1 diabetes mellitus.